Evidence map›Paper›PMID 39714724›Full record

ReviewInflammopharmacology2025

Across-the-board review on Omicron SARS-CoV-2 variant.

Rufaida Wasim, Sumaiya, Asad Ahmad

Abstract readReview
PubMed Publisher
In one paragraph

Review in Inflammopharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Rufaida WasimDepartment of Pharmacy, Integral University, Lucknow, 226026, India. rufaidaw@iul.ac.in.ORCID http://orcid.org/0009-0000-4840-1696
SumaiyaCareer Post Graduate Institute of Dental Sciences and Hospital, Lucknow, India.
Asad AhmadDepartment of Pharmacy, Integral University, Lucknow, 226026, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionCoronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has resulted in a cataclysmic pandemic. Several SARS-CoV-2 mutations have been found and reported since the COVID-19 pandemic began. After the Alpha, Beta, Gamma, and Delta variants, the Omicron (B.1.1.529) is the most recently emerged variant of concern (VOC), which has evolved as a result of a high number of mutations, particularly in the spike protein, raising concerns about its ability to evade pre-existing immunity acquired through vaccination or natural infection.

methodsThis is a review based on studies published from November 2021 to September 2024. RESULT AND DISCUSSIONS: The current article discusses the advent of the SARS-CoV-2 Omicron variant, its key characteristics and significant global health concerns, as well as measures for dealing with it in the context of the continuing COVID-19 pandemic. Various mutations in Omicron have been discussed that contribute to increased transmissibility and immune evasion from vaccine-induced or natural immunity acquired after infection. To understand the similarities and differences between different VOCs and Omicron, we conducted a comparative investigation.

conclusionStrengthening research, improving genomic surveillance and tracking, developing highly effective vaccines and immunotherapies, designing appropriate strategies, action plans, and future preparedness plans must all be prioritized and implemented quickly at global levels to mitigate the high global health concerns associated with the emergence of this new Omicron variant well before it causes large-scale COVID-19 outbreaks.

Indexed as

COVID-19SARS-CoV-2COVID-19 VaccinesHumansImmune EvasionMutationSpike Glycoprotein, CoronavirusCOVID-19 VaccinesSpike Glycoprotein, CoronavirusB.1.1.529COVID-19OmicronSARS-CoV-2Variant of interestVariants of concern

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.